Friday, 13 November 2026European Markets

Energy Security

3 articles

Nine Weeks of Hormuz Closure Risks 1970s-Scale Energy Shock for Europe

Nine Weeks of Hormuz Closure Risks 1970s-Scale Energy Shock for Europe

The Strait of Hormuz closure is entering its ninth week following a US-Israel military strike on Iran, with economists comparing the shock to the 1970s oil crises. Stagflation risks are mounting as demand destruction spreads from Asian markets into Western economies. European policymakers face constrained options as inflation pressure collides with already-fragile growth.

LM Salvado•
Economists Warn Middle East Conflict Could Trigger 1970s-Style Oil Shock for Europe

Economists Warn Middle East Conflict Could Trigger 1970s-Style Oil Shock for Europe

A Middle East conflict threatening the Strait of Hormuz has drawn warnings from top economists of an energy crisis rivalling the 1970s. IMF chief economist Pierre-Olivier Gourinchas says the shock could drive unemployment and food insecurity across multiple countries. Without a resolution, economist Justin Wolfers warns elevated energy costs could persist for years — a direct threat to Europe's energy-dependent economy.

LM Salvado•
Hormuz blockade removes 20M barrels daily, pushing UK mortgage rates up as inflation delays easing until 2026

Hormuz blockade removes 20M barrels daily, pushing UK mortgage rates up as inflation delays easing until 2026

The Middle East conflict has cut 20 million barrels per day from global oil markets through a Hormuz Strait blockade, according to MacroEdge Research. Resulting inflationary pressure is forcing the Bank of England to hold rates at 3.75% while UK mortgage lenders raise borrowing costs, with Federal Reserve officials warning price pressures won't ease before late 2026.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com